a16z advisor: Only 1.3% of political contracts in prediction markets have liquidity, suggests introducing AI agents to provide liquidity
According to Odaily, Andy Hall, professor at Stanford Business School and advisor to a16z & Meta, stated on the X platform that his team has established a new dataset focused on political prediction markets, liquidity, and settlement rules. The research found that the vast majority of political contracts in prediction markets lack activity, with only 1.3% of contracts having sufficient liquidity. Kalshi and Polymarket rarely list identical contracts with the same rules, leading to further fragmentation of liquidity.
Andy Hall proposed four improvement suggestions: First, list contracts on core issues and cooperate with independent institutions to define markets of social concern; second, pay fees to market makers to inject initial liquidity into political markets; third, introduce AI agents to trade in areas where humans do not participate, generating price references needed by society; fourth, establish unified definitions and settlement rules across platforms. Andy Hall believes that these measures will attract traders seeking to hedge political risks and make prediction markets the truth machines that society needs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
